Chronic allograft rejection: A fresh look

Current Opinion in Organ Transplantation

Volumn 20, Issue 1, 2015, Pages 13-20

  Wedel, Johannes ^a,b   Bruneau, Sarah ^a,b   Kochupurakkal, Nora ^a,b   Boneschansker, Leo ^a,b   Briscoe, David M ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

chronic allograft rejection; endothelial cells; neuropilins; T cells; vascular endothelial growth factor

Indexed keywords

ALLOANTIBODY; CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; NEUROPILIN 1; PROTEIN KINASE B; SEMAPHORIN; VASCULOTROPIN;

ALLOIMMUNITY; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; ENDOTHELIUM CELL; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; HYPOXEMIA; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; MICROENVIRONMENT; MICROVASCULATURE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ALLOGRAFT; ANIMAL; CHRONIC DISEASE; GRAFT REJECTION; ORGAN TRANSPLANTATION;

ALLOGRAFTS; ANIMALS; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION;

EID: 84921413922     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000155     Document Type: Review

References (95)

1. United Network for Organ Sharing. https://unos.org. Accessed 30 October 2014.
2. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333.
3. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14:387-397.
4. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study. Am J Transplant 2010; 10:324-330.
5. Pober JS, Jane-wit D, Qin L, Tellides G. Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy. Arterioscler Thromb Vasc Biol 2014; 34:1609-1614.
6. Bruneau S, Woda CB, Daly KP, et al. Key features of the intragraft microenvironment that determine long-Term survival following transplantation. Front Immunol 2012; 3:54.
7. Al-Lamki RS, Bradley JR, Pober JS. Endothelial cells in allograft rejection. Transplantation 2008; 86:1340-1348.
8. Dormond O, DufourM, Seto T, et al. Targeting the intragraft microenvironment and the development of chronic allograft rejection. Hum Immunol 2012; 73:1261-1268.
9. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibodymediated rejection in human kidney transplants. Am J Transplant 2013; 13:971-983.
10. Reed EF. Mechanisms of action and effects of antibodies on the cells of the allograft. Hum Immunol 2012; 73:1211-1212.
11. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312-2323.
12. Sidky YA, Auerbach R. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction. J Exp Med 1975; 141:1084-1100.
13. Polverini PJ, Cotran PS, Gimbrone MA Jr, Unanue ER. Activated macrophages induce vascular proliferation. Nature 1977; 269:804-806.
14. Contreras AG, Briscoe DM. Every allograft needs a silver lining. J Clin Invest 2007; 117:3645-3648.
15. Babu AN, Murakawa T, Thurman JM, et al. Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J Clin Invest 2007; 117:3774-3785.
16. Moulton KS, Melder RJ, Dharnidharka VR, et al. Angiogenesis in the huPBLSCID model of human transplant rejection. Transplantation 1999; 67:1626-1631.
17. Jindra PT, Jin YP, Jacamo R, et al. MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway. Biochem Biophys Res Commun 2008; 369:781-787.
18. Reinders ME, Sho M, Robertson SW, et al. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol 2003; 171:1534-1541.
19. Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 2006; 17:932-942.
20. Zhang X, Rozengurt E, Reed EF. HLA class I molecules partner with integrin beta4 to stimulate endothelial cell proliferation and migration. Sci Signal 2010; 3:ra85.
21. Maier CL, Pober JS. Human placental pericytes poorly stimulate and actively regulate allogeneic CD4 T cell responses. Arterioscler Thromb Vasc Biol 2011; 31:183-189.
22. Jiang X, Khan MA, Tian W, et al. Adenovirus-mediated HIF-1alpha gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest 2011; 121:2336-2349.
23. Jiang X, Sung YK, Tian W, et al. Graft microvascular disease in solid organ transplantation. J Mol Med 2014; 92:797-810.
24. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-To-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13:952-961.
25. Lin SL, Chang FC, Schrimpf C, et al. Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 2011; 178:911-923.
26. Reinders ME, Sho M, Izawa A, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112:1655-1665.
27. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91:1071-1121.
28. Semenza GL. Regulation of vascularization by hypoxia-inducible factor 1. Ann N Y Acad Sci 2009; 1177:2-8.
29. PoznanskyMC, Olszak IT, Foxall R, et al. Active movement of T cells away from a chemokine. Nat Med 2000; 6:543-548.
30. Selvaraj SK, Giri RK, Perelman N, et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003; 102:1515-1524.
31. Dewerchin M, Carmeliet P. PlGF: a multitasking cytokine with diseaserestricted activity. Cold Spring Harb Perspect Med 2012; 2:a011056.
32. Daly KP, Seifert ME, Chandraker A, et al. VEGF-C VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant 2013; 32:120-128.
33. Santana-Rodriguez N, Garcia-Herrera R, Clavo B, et al. Searching for novel molecular targets of chronic rejection in an orthotopic experimental lung transplantation model. J Heart Lung Transplant 2012; 31:213-221.
34. Peng W, Chen J, Jiang Y, et al. Noninvasive detection of acute renal allograft rejection by measurement of vascular endothelial growth factor in urine. J Int Med Res 2007; 35:442-449.
35. Girnita DM, Brooks MM, Webber SA, et al. Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multiinstitutional study. Transplantation 2008; 85:1632-1639.
36. Aharinejad S, Krenn K, Zuckermann A, et al. Serum matrix metalloprotease-1 and vascular endothelial growth factor-A predict cardiac allograft rejection. Am J Transplant 2009; 9:149-159.
37. Lemstrom KB, Krebs R, Nykanen AI, et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002; 105:2524-2530.
38. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-936.
39. Zhang J, Silva T, Yarovinsky T, et al. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res 2010; 107:408-417.
40. Basu A, Hoerning A, Datta D, et al. Cutting edge: vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol 2010; 184:545-549.
41. Edelbauer M, Datta D, Vos IH, et al. Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo. Blood 2010; 116:1980-1989.
42. Sarris M, Andersen KG, Randow F, et al. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008; 28:402-413.
43. Bruder D, Probst-Kepper M, Westendorf AM, et al. Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004; 34:623-630.
44. Suzuki H, Onishi H, Wada J, et al. VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol 2010; 40:197-203.
45. Yadav M, Louvet C, Davini D, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 2012; 209:1713-1722; S1-19.
46. Sho M, Akashi S, Kanehiro H, et al. Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo. Transplantation 2005; 80:717-722.
47. Sihvola RK, Tikkanen JM, Krebs R, et al. Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. Transplantation 2003; 75:334-339.
48. Malmstrom NK, Kallio EA, Rintala JM, et al. Vascular endothelial growth factor in chronic rat allograft nephropathy. Transpl Immunol 2008; 19:136-144.
49. Mukhopadhyay D, Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer BiolV 14 2004; 123-130.
50. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10:159-170.
51. Contreras AG, Dormond O, Edelbauer M, et al. mTOR-understanding the clinical effects. Transplant Proc 2008; 40 (10 Suppl):S9-S12.
52. Mendes-da-Cruz DA, Brignier AC, Asnafi V, et al. Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors. PLoS One 2014; 9:e103405.
53. Curreli S, Arany Z, Gerardy-Schahn R, et al. Polysialylated neuropilin-2 is expressed on the surface of human dendritic cells and modulates dendritic cell-T lymphocyte interactions. J Biol Chem 2007; 282:30346-30356.
54. Bagri A, Tessier-Lavigne M. Neuropilins as semaphorin receptors: in vivo functions in neuronal cell migration and axon guidance. Adv Exp Med Biol 2002; 515:13-31.
55. Kolodkin AL, Levengood DV, Rowe EG, et al. Neuropilin is a semaphorin III receptor. Cell 1997; 90:753-762.
56. Chen H, Chedotal A, He Z, et al. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 1997; 19:547-559.
57. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92:735-745.
58. Geretti E, Shimizu A, Kurschat P, Klagsbrun M. Site-directed mutagenesis in the B-neuropilin-2 domain selectively enhances its affinity to VEGF165, but not to semaphorin 3F. The J Biol Chem 2007; 282:25698-25707.
59. Takashima S, Kitakaze M, Asakura M, et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A 2002; 99:3657-3662.
60. Bielenberg DR, Hida Y, Shimizu A, et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 2004; 114:1260-1271.
61. Delgoffe GM, Woo SR, Turnis ME, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 2013; 501:252-256.
62. Weiss JM, Bilate AM, Gobert M, et al. Neuropilin 1 is expressed on thymusderived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med 2012; 209:1723-1742; S1.
63. Hansen W, Hutzler M, Abel S, et al. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med 2012; 209:2001-2016.
64. Battaglia A, Buzzonetti A, Monego G, et al. Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology 2008; 123:129-138.
65. Tamagnone L, Comoglio PM. Signalling by semaphorin receptors: cell guidance and beyond. Trends Cell Biol 2000; 10:377-383.
66. Catalano A, Caprari P, Moretti S, et al. Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 2006; 107:3321-3329.
67. Becker PM, Tran TS, Delannoy MJ, et al. Semaphorin 3A contributes to distal pulmonary epithelial cell differentiation and lung morphogenesis. PLoS One 2011; 6:e27449.
68. Tufro A. Semaphorin3a signaling, podocyte shape, and glomerular disease. Pediatr Nephrol 2014; 29:751-755.
69. Antipenko A, Himanen JP, van Leyen K, et al. Structure of the semaphorin-3A receptor binding module. Neuron 2003; 39:589-598.
70. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 2008; 8:632-645.
71. Moretti S, Procopio A, Boemi M, Catalano A. Neuronal semaphorins regulate a primary immune response. Curr Neurovasc Res 2006; 3:295-305.
72. Solomon BD, Mueller C, Chae WJ, et al. Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2011; 108:2040-2045.
73. Yuan Q, Hong S, Shi B, et al. CD4(+)CD25(-)Nrp1(+) T cells synergize with rapamycin to prevent murine cardiac allorejection in immunocompetent recipients. PLoS One 2013; 8:e61151.
74. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-135.
75. Wang C, Qin L, Manes TD, et al. Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2. J Exp Med 2014; 211:395-404.
76. Wang C, Yi T, Qin L, et al. Rapamycin-Treated human endothelial cells preferentially activate allogeneic regulatory T cells. J Clin Invest 2013; 123:1677-1693.
77. Bruneau S, Nakayama H, Woda CB, et al. DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood 2013; 122:1833-1842.
78. Dormond O, Contreras AG, Meijer E, et al. CD40-induced signaling in human endothelial cells results in mTORC2-And Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol 2008; 181:8088-8095.
79. Murao K, Ohyama T, Imachi H, et al. TNF-Alpha stimulation of MCP-1 expression is mediated by the Akt/PKB signal transduction pathway in vascular endothelial cells. Bioch Biophys Res Commun 2000; 276:791-796.
80. Boulday G, Haskova Z, Reinders ME, et al. Vascular endothelial growth factorinduced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol 2006; 176:3098-3107.
81. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236:219-242.
82. Jindra PT, Jin YP, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008; 180:2357-2366.
83. Valenzuela NM, Hong L, Shen XD, et al. Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant 2013; 13:299-311.
84. Jin YP, Valenzuela NM, Ziegler ME, et al. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. Am J Transplant 2014; 14:806-819.
85. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137:873-886.
86. Hottenrott MC, Wedel J, Gaertner S, et al. N-octanoyl dopamine inhibits the expression of a subset of kappaB regulated genes: potential role of p65 Ser276 phosphorylation. PLoS One 2013; 8:e73122.
87. Losel RM, Schnetzke U, Brinkkoetter PT, et al. N-octanoyl dopamine, a nonhemodyanic dopamine derivative, for cell protection during hypothermic organ preservation. PLoS One 2010; 5:e9713.
88. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105:4743-4748.
89. Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30:832-844.
90. Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nature Immunol 2011; 12:295-303.
91. Zeng H, Yang K, Cloer C, et al.mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature 2013; 499:485-490.
92. Thoreen CC, Sabatini DM. Rapamycin inhibits mTORC1, but not completely. Autophagy 2009; 5:725-726.
93. Procaccini C, De Rosa V, Galgani M, et al. An oscillatory switch inmTOR kinase activity sets regulatory T cell responsiveness. Immunity 2010; 33:929-941.
94. Guan F, Villegas G, Teichman J, et al. Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival. Kidney Int 2006; 69:1564-1569.
95. Boneschansker L, Yan J, Wong E, et al. Microfluidic platform for the quantitative analysis of leukocyte migration signatures. Nat Commun 2014; 5:4787.